Effect of Midazolam as Premedication in Patients Undergoing Breast Conservation Surgery
European Journal of Clinical Pharmacy · 30.12.2025 · 7 (1) · 5705-5711
DOI: 10.61336/ejcp/25-12-656 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Pharmacy, online erschienen am 30.12.2025.
Abstract (Originalsprache)
Background
Anxiety before surgery is prevalent in women with breast cancer, which can become a source of unfavorable outcomes in the perioperative setting. While benzodiazepines are common medications administered in pharmacological anxiolysis, their efficacy is questionable in adult surgical patients.
Objective
To investigate whether intravenous midazolam (0.05 mg/kg) premedication can suppress the preoperative state of anxiety as assessed by the Amsterdam Preoperative Anxiety and Information Scale (APAIS) and enhance postoperative satisfaction as measured by the Leiden Perioperative Patient Satisfaction questionnaire (LPPSq) in female patients with breast conserving surgical procedures.
Methods
In this single-blind randomized controlled clinical study, 124 female participants scheduled to undergo breast conservation surgery received intravenous midazolam (62) or a saline placebo (62) before anesthetic induction after random allocation to treatment groups. Anxiety was measured using the APAIS before and after the administration of the medication. The LPPSq study for postoperative satisfaction was performed on the day of surgery or the first postoperative day. The study used the independent t-test and chi-square test for analysis with a significance threshold of p < 0.05.
Results
The demographic and clinical factors, and APAIS scores at baseline, were not significantly different among the groups (p > 0.05). The APAIS scores following premedication were found to be lower in the midazolam group than the placebo group (baseline scores: 9.5 ± 2.5 vs. 13.8 ± 2.9; p < 0.001). None of the patients in the midazolam group had scores for very high anxiety levels, whereas 9 (14.5%) of patients receiving the placebo had scores for high anxiety levels (p = 0.005). The mean LPPSq scores were also higher among patients of the midazolam group (85.2 ± 8.4 vs. 78.0 ± 10.1; p < 0.001), and more patients expressed satisfaction. There were no adverse events reported.
Conclusion
Premedication with midazolam is efficacious in reducing preoperative anxiety and increasing patient satisfaction after breast-conserving surgery in women. The results establish its selective usage as an anxiolytic agent, but caution is recommended while administering it, particularly in the elderly or fragile population.
Zitieren
APA
(2025). Effect of Midazolam as Premedication in Patients Undergoing Breast Conservation Surgery. European Journal of Clinical Pharmacy, 7(1), 5705-5711. https://doi.org/10.61336/ejcp/25-12-656
Vancouver
Effect of Midazolam as Premedication in Patients Undergoing Breast Conservation Surgery. European Journal of Clinical Pharmacy. 2025;7(1):5705-5711. doi:10.61336/ejcp/25-12-656
BibTeX
@article{euvimed2025,
title = {Effect of Midazolam as Premedication in Patients Undergoing Breast Conservation Surgery},
journal = {European Journal of Clinical Pharmacy},
year = {2025},
volume = {7},
number = {1},
pages = {5705--5711},
doi = {10.61336/ejcp/25-12-656}
}
EUVIMED